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Highlights: 
 
 Vinorelbine chemotherapy with G-CSF is a reliable and effective mobilization regimen 
in myeloma patients.  
 However, a single vinorelbine administration is adding significant neurotoxicity in 
bortezomib-pretreated myeloma patients. 
 Aggravation of bortezomib-induced neuropathy was observed in 17%, and first 
occurrence of polyneuropathy in additional 7% patients.  
 Development of polyneuropathy was not associated with differing survival rates.  
 The efficacy of vinorelbine mobilization should be balanced against its neurotoxic 
potential.  
 
Highlights (for review)
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ABSTRACT  
 
Vinorelbine chemotherapy with G-CSF stimulation is the standard mobilization regimen in 
Switzerland for multiple myeloma patients. However, with the increasing use of bortezomib 
during induction treatment, adding the neurotoxic compound vinorelbine for mobilization may 
aggravate bortezomib-induced polyneuropathy. In this retrospective single-center study, we 
aimed to explore vinorelbine mediated neuropathy in 106 consecutive bortezomib pretreated 
myeloma patients. We confirmed that vinorelbine with G-CSF represents a reliable and 
effective regimen for mobilization of autologous stem cells. However, the single 
administration of 35mg/m2 vinorelbine added significant neurotoxicity. We found that 24 
patients (24%) reported vinorelbine mediated neurotoxicity: Aggravation of bortezomib-
induced neuropathy was observed in 17 patients (17%), and vinorelbine mobilization induced 
first occurrence of polyneuropathy in additional 7 patients (7%). We observed that 
development of polyneuropathy was not associated with differing survival rates. Finally, 
affected patients reported polyneuropathy associated disease burden as “very high” in 13% 
and “high” in 50%. Our data indicate that a single administration of vinorelbine to mobilize 
autologous stem cells is associated with significant additional polyneuropathy in bortezomib 
pretreated myeloma patients. The efficacy of vinorelbine mobilization should be balanced 
against its neurotoxic potential.  
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1. INTRODUCTION 
 
Treatment algorithms for multiple myeloma (MM) patients have rapidly evolved in the last 
decade. Introduction of thalidomide, bortezomib or lenalidomide into induction treatment, the 
routine use of high-dose chemotherapy (HDCT) followed by autologous stem cell 
transplantation (ASCT), and subsequent consolidation and maintenance treatment with 
bortezomib or lenalidomide have markedly improved prognosis of young myeloma patients 
1,2. In particular, the response to induction treatment has been increasingly improved with 
impressive rates of complete remission. Also, HDCT with ASCT continues to add 
independent additional benefit in the era of novel agents, and, finally, maintenance treatment 
after HDCT was demonstrated to significantly prolong progression-free survival and – at least 
in some studies – also overall survival 3,4. Thus, HDCT supported by ASCT remains a 
cornerstone of the standard treatment algorithms for myeloma patients aged below 65 years 
1,5. 
For the collection of autologous hematopoietic stem cells, the use of peripheral blood 
stem cells has become the preferred procedure. However, the optimal strategy to mobilize 
autologous stem cells from the bone marrow to the peripheral blood remains controversial 
6. CD34+ cells can effectively be mobilized with granulocyte colony-stimulating factor (G-
CSF) alone or in combination with chemotherapy, or - in patients with insufficient mobilization 
potential - together with the stem cell mobilizing compound plerixafor, with combinations of 
these modalities being superior compared to G-CSF alone. Given the costs of plerixafor, the 
combination of chemotherapy with G-CSF remains a widely used strategy. Whereas high-
dose cyclophosphamide chemotherapy with G-CSF represents the most commonly used 
chemomobilization regimen, the combination of G-CSF with a single dose of non-
myelosuppressive chemotherapy with vinorelbine (35mg/m2) represents the standard 
mobilization regimen in Switzerland since a decade 7-10. Its advantages compared to 
cyclophosphamide mobilization include a highly predictable collection rate at day 8, its strictly 
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ambulatory setting, and the lack of febrile complications notoriously associated with 
cyclophosphamide mobilization 7-10.  
With the predominant use of bortezomib during induction treatment and with 
chemotherapy-induced polyneuropathy (CIPN) as its limiting side effect, the use of 
vinorelbine might have become increasingly problematic because of its additional 
neurotoxicity 11-13. Severe aggravation of pre-existing peripheral neurotoxicity (such as 
diabetic, alcoholic or inherited neuropathy) and CIPN in patients with concomitant or previous 
treatment with other neurotoxic chemotherapy compounds such as paclitaxel have been 
reported following vinorelbine treatment 11,14-16. These facts led us to evaluate 
vinorelbine-induced CIPN following mobilization treatment in MM patients. 
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2. MATERIALS AND METHODS 
 
2.1 Patients and study design:  
This single-center retrospective study comprised all consecutive myeloma patients 
undergoing first-line consolidation with high-dose melphalan chemotherapy (HDCT) and 
autologous stem cell transplantation (ASCT) who were mobilized with a single dose of 
vinorelbine between 01/2005 and 01/2013. This study was restricted to patients who 
received a bortezomib-based induction treatment. Patient characteristics at diagnosis are 
summarized in Table 1 including information on the chemotherapy regimens used. This 
study was approved by the local ethics committee of Berne, Switzerland (decision 
#143/2014).  
Data sources were medical records of the patients. In addition, a detailed 
questionnaire assessing existence and severity of neuropathy was sent to patients who 
underwent the mobilization procedure between 01/2011 and 01/2013. The purpose of this 
questionnaire was to gather information on the subjective disease burden of chemotherapy 
induced polyneuropathy, but also to verify the information retrieved from the medical records. 
We decided against sending the questionnaire to patients mobilized before January 2011 as 
such an analysis might have generated unreliable information. Accordingly, 41 
questionnaires were sent out, with a 100% response rate.  
 
2.2 Stem cell chemomobilization and transplantation procedure:  
Vinorelbine was given to all patients as a 10 minute infusion at 35 mg/m2 on day 1. 
Filgrastim (G-CSF) was administered subcutaneously at a dose of 1 Mio U/kg/day divided 
into two daily doses. It was started on day 4 and continued until the day of stem cell 
collection. Apheresis was consistently initiated at the first day when the peripheral blood 
CD34+ cell count exceeded 10’000 cells/ml. A minimum of 2x106 collected CD34+cells/kg 
b.w. was required. Cell processing procedures followed local standards. All patients 
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underwent high-dose chemotherapy with melphalan administered intravenously at a dose of 
200mg/m2 with peripheral stem cell transplantation at the following day.  
 
2.3 Definitions:  
The primary endpoint of the study was CIPN following vinorelbine mobilization treatment. We 
assessed CIPN occurring during induction, mobilization, high-dose and maintenance 
treatment. We analyzed incidence, severity, localization, and specific treatment. CIPN during 
mobilization chemotherapy was defined as vinorelbine-induced, when patients presented 
novel or increased symptoms within seven days after its administration. CIPN during 
bortezomib-based induction treatment was defined, when it occurred between the first 
bortezomib administration and up to 30 days after the last dose. Quality and severity of CIPN 
were assessed according to the modified version of the National Cancer Institute Common 
Toxicity Criteria for Adverse Events (NCI-CTCAE; version 4.03). The following categories 
were assessed: general sensory neuropathy (paresthesia, dysesthesia, hypesthesia, 
hyperesthesia, hyporeflexia, hypalgesia, and decreased temperature sensation); neuropathic 
pain; general motoric neuropathy (muscle weakness); fasciculation (including tremor and 
spasm); and ataxia. We also determined the need for specific analgetic CIPN medication as 
well as modification or interruption of myeloma specific treatment to control CIPN symptoms.  
 
2.4 Statistical analysis:  
Descriptive statistics were used to calculate variables. For continuous variables, we 
summarized number of observations, median and range. For categorical data, number and 
percentage of patients in each category were calculated. We compared nominal variables 
with Fisher exact tests. For continuous variables, we used non-parametric Mann-Whitney-U 
tests. Response rates were defined according to the IMWG criteria. OS was defined as the 
time from transplantation until the date of death from any cause or of the last follow-up for 
patients alive. PFS was defined as the time from transplantation to first progression, relapse 
or death whichever occurred first and patients without progression or death were censored at 
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their last follow-up. Time-to-event estimates (PFS, OS) were designed according to the 
Kaplan-Meier method using the log-rank (Mantel-Cox) test. Data cut-off date was March 1, 
2013. All p-values were two-sided. A P-value less than .05 was considered statistically 
significant. All analyses were performed using the GraphPadPrism software (Version 6.0b, 
GraphPad Software, Inc, San Diego, CA).  
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3. RESULTS 
 
3.1 Patient demographics, baseline characteristics and treatment regimens:  
In this cohort, we investigated 106 consecutive myeloma patients who received bortezomib-
based first-line induction chemotherapy and who were subsequently mobilized using a 
vinorelbine-based regimen. Patient characteristics at diagnosis and details on the 
chemotherapy regimens are summarized in Table 1. The median age at diagnosis of the 
patients in our cohort was 58 years (range 39-69 years). Patients mostly had IgG subtype 
(68%), kappa light chain involved (58%), and ISS stage I (41%). Cytogenetic analyses were 
available in 55 patients (52%), with high-risk abnormalities in 36 of these 55 patients (65%).  
62 of the 106 patients (59%) received an induction regimen with bortezomib / 
dexamethasone (VD), 27 patients (25%) had a combination of bortezomib / 
cyclophosphamide / dexamethasone (VCD), 12 patients (11%) had a regimen with 
bortezomib / doxorubicin / dexamethasone (PAD), 2 patients (2%) had bortezomib / 
thalidomide / dexamethasone (VTD), and 3 patients (3%) were treated with bortezomib / 
lenalidomide / dexamethasone (VRD), respectively. Bortezomib was given at a dose of 1.3 
mg/m2 at days 1, 4, 8 and 11 every three weeks. Until 12/2010, bortezomib was administered 
intravenously, whereas it was given subcutaneously since 01/2011. For patients developing 
neuropathy, bortezomib treatment was first modified in terms of dose (1.0 mg/m2, then 0.8 
mg/m2), and second altered to a once weekly schedule. 45 patients (42%) received 
maintenance treatment most frequently with lenalidomide (93%), and in 7% with bortezomib.  
 
3.2 Mobilization, apheresis and transplantation:  
Mobilization, apheresis and transplantation details are given in Table 2. 75 patients (71%) 
received a mobilization treatment with vinorelbine and G-CSF (VG), 21 patients (20%) had 
vinorelbine and plerixafor (VP) without G-CSF, and 10 patients (9%) received a combination 
of vinorelbine, G-CSF and plerixafor (VGP). In 92 patients (87%), a single day apheresis 
procedure was sufficient to collect the target number of at least 2 x 106 CD34+cells/kg body 
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weight (b.w.), whereas 14 patients (13%) needed two collection days. Apheresis was started 
after a median of 8 days (range 7 to 16 days) after mobilization with vinorelbine, and it was 
accomplished within a median of 228 minutes (range 70 to 453 minutes). The median final 
CD34+ apheresis yield was 13.55 x 106 cells/kg b.w. (range 3.09 to 37.33). More than 10 x 
106 CD34+ cells/kg b.w. were collected in 75% of patients. 
All patients ultimately proceeded to HDCT with melphalan and ASCT, and patients 
received a median of 4.34 x 106 CD34+ cells/kg b.w. (range 2.04 to 8.45). All patients had 
successful engraftment. The median time to recovery was 12 days (range 10 to 15 days) for 
neutrophils, 13 days (range 8 to 23 days) for platelets > 20x109/l, and 21 days (range 14 to 
87 days) for platelets > 100x109/l.  
 
3.3 Chemotherapy induced polyneuropathy (CIPN):  
The incidence of CIPN during induction and mobilization treatment is summarized in Table 3. 
In five patients (5%), polyneuropathy was pre-existing - due to diabetes mellitus, was 
myeloma-associated or had an unknown cause. More than half of all patients developed 
CIPN during bortezomib-based induction treatment: Non-significant differences were 
observed in the total incidence of CIPN as documented by the treating physicians in their 
medical charts (58%) compared to the data retrieved from individual questionnaires (62%; P 
= .4561).  
CIPN symptoms were first reported after a median of seven weeks of bortezomib 
treatment according to the physician’s charts as compared to patients reporting in their 
questionnaire the onset of symptoms already after four weeks (P = .0232). As depicted in 
Table 4, CIPN affected patients predominantly reported sensory symptoms (95%), with 
grade I/II in 78% and grade III/IV in 22%. Mild to severe neuropathic pain was documented in 
24%. Motoric symptoms were underreported in the medical records compared to the 
questionnaires, with muscle weakness (10% versus 37%; P = .0050), and with spasms, 
tremor or fasciculations in 10% versus 30% (P = .0263). Whereas physicians rarely 
documented ataxia (5%), 22% of the patients reported signs of ataxia (P = .0205). In 
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conclusion, as compared to individual questionnaires, medical records congruently 
documented the total incidence of CIPN and the occurrence of sensory deficits as the 
predominant form of CIPN, but not additional manifestations of CIPN in affected patients. 
Any kind of treatment for CIPN was noted in 30% based on medical charts, but was 
reported in 44% in the patient questionnaires (P = .0387). Medication predominantly 
comprised pregabalin, gabapentin and opioids. Finally, 19% of all patients needed 
bortezomib dose reduction, prolongation of treatment interval or even interruption of therapy. 
In 13% of all patients, CIPN resulted in the discontinuation of bortezomib treatment.  
The development of CIPN following vinorelbine mobilization chemotherapy is 
presented in Table 3.  Based on medical charts, 24 of 106 patients (23%) reported CIPN 
following vinorelbine mobilization chemotherapy (17 patients reported worsening of pre-
existing CIPN and 7 patients developed novel CIPN); in accordance, 11 (of 41) patients 
(27%) also reported this in their questionnaire (P = .6668). Details of CIPN during 
mobilization are given in Table 4. Sensory deficits were reported in 96% (n=23) of the 
patients, with grade I/II in 61%, and in 39% with grade III/IV. Neuropathic pain was observed 
in 33%, with grade III/IV in 75% of affected patients. Again, patients reported motoric deficits 
more frequently in the questionnaires both for motoric PN (36%) and 
spasms/tremor/fasciculations (45%) compared to the medical records with 0% for motoric 
CIPN and 13% for spasms/tremor/fasciculations (P = .0063, and P = .0767, respectively). 
Ataxia was not reported in the medical charts, but 18% of patients in the questionnaire 
experienced ataxia during mobilization therapy (P = .0924). 50% of all patients needed 
analgesic medication medication such as pregabalin, gabapentin, paracetamol or metamizol 
against CIPN following vinorelbine mobilization chemotherapy.   
Reporting of new or worsening of CIPN due to HDCT was rare, with 5% according to 
the medical charts (Table 3). Similarly, the rate of new or worsening of pre-existing CIPN 
caused by maintenance treatment was low, with an incidence of 13% in the medical charts 
versus 10% in the questionnaire (P = .7302). Both patients in our cohort treated with 
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thalidomide maintenance also developed CIPN, compared to 10% of all patients treated with 
lenalidomide maintenance (Table 3). 
Follow-up information on the course of CIPN was available for all patients who 
developed CIPN during the treatment procedure and who participated in the questionnaire 
part of the study. 5% of all patients with CIPN became asymptomatic with the end of HDCT, 
and in 22% symptoms improved gradually over time with a median time to improvement of 3 
months (range 1 to 8 months). However, 31% of the patients in the questionnaire reported a 
partial improvement of CIPN, and 31% of the patients with CIPN reported unchanged 
symptoms. Patients described a “very high burden” due to CIPN in 13%, and a “high burden” 
in 50%. For 31% of the patients, CIPN was “tolerable and modest”, whereas only 6% 
considered it “harmless” (data not shown). 
 
3.4 Response to treatment and outcome:  
When comparing patients with and without CIPN before ASCT, we observed non-significant 
differences in the response rates before ASCT between these groups: The CR, VGPR, and 
PR rates were 10% versus 19%, 13% versus 25% and 73% versus 56%, respectively. Also, 
we found non-significant differences in the response rates between the two groups 100 days 
after ASCT, with the CR rates tending to be lower in patients with CIPN (with 43% versus 
62%; P =.0722). 
The group of myeloma patients with CIPN had a longer follow-up (23 versus 16 
months; P = .0294). Figure 1A depicts the progression-free survival (PFS) of the two groups, 
and Figure 1B indicates the overall survival (OS). We observed no significant differences in 
survival rates. The median PFS of patients with CIPN was 16 months (range 1 to 59 moths) 
compared to 12 months (range 1 to 79 months) of patients without CIPN (P = .6906); and the 
median OS of patients with CIPN was 23 months (range 1 to 64) compared to 17 months 
(range 1 to 79) of patients without CIPN (P =.8761).  
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4. DISCUSSION  
 
Current practice in Switzerland for stem and progenitor cell mobilization in myeloma patients 
consists in the combination of chemotherapy with vinorelbine and daily G-CSF administration 
followed by stem cell apheresis consistently scheduled on day 8. The advantages of this 
strategy compared to cyclophosphamide mobilization include a highly predictable collection 
rate at day 8, its strictly ambulatory setting, and the lack of febrile complications notoriously 
associated with cyclophosphamide mobilization. This – to some degree local – strategy has 
been challenged in the last years with the predominant use of bortezomib during induction 
treatment and with bortezomib induced polyneuropathy (CIPN) as its major side effect. This 
study aimed to investigate concerns on the use of vinorelbine in myeloma patients presenting 
with bortezomib mediated CIPN. In fact, we found in our cohort of 106 consecutive 
bortezomib pretreated myeloma patients that a single administration of 35 mg/m2 vinorelbine 
added significant neurotoxicity. We observed in 24% of all patients vinorelbine caused 
neurotoxicity. Aggravation of bortezomib-induced neuropathy was observed in 17%, and 
vinorelbine mobilization induced first occurrence of polyneuropathy in 7%.  
The use of bortezomib-based regimens during first-line induction treatment has 
become standard of care for myeloma patients, with CIPN being its major and often limiting 
side effect 17-23. Consequently, grade 3-4 neuropathy was reported in 4% to 27% in 
pevious series, and we observed a frequency of 23% in our cohort. In addition, we found in 
bortezomib-treated myeloma patients the development of novel (or worsening of pre-existing) 
neuropathy in 58% of all patients. The majority of the patients had sensory deficits which is 
consistent with previous reports on bortezomib inducing a dose-related peripheral mainly 
sensory polyneuropathy with accompanying neuropathic pain 17-23. A surprising finding of 
our study was that patients in our cohort tended to report motoric impairment more frequently 
(37%) if asked in detail whereas such deficits were previously reported to occur in only up to 
10% of the patients 17. Similar findings were observed for the development of ataxia. Most 
liekly, physicians are impressed by the more frequent sensory deficits often associated with 
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neuropathic pains leading to underreporting of signs of motoric neuropathy such as muscle 
weakness, spasms, fasciculations or tremor 17. 
Our data suggest that a single administration of 35 mg/m2 of vinorelbine mobilization 
treatment can induce relevant additional or novel neurotoxicity in a significant proportion of 
bortezomib-pretreated myeloma patients. Vinorelbine mediated neurotoxicity is considered to 
be less frequent compared to other vinca-alkaloids. Vinca-alkaloids mediate neurotoxicity 
based on their affinity for β-tubulin, the subunit of microtubules, thereby suppressing not only 
the dynamics of the mitotic spindle, but also leading to destabilization of the axonal 
microtubules and consequently to axonal damage 11,13,24,25. Vinorelbine is considered to 
cause less neurotoxicity than other vinca-alkaloids due to a more selective binding to mitotic 
than to axonal microtubules, and therefore higher concentrations of the drug are needed to 
cause neurotoxicity 13,26-29. In fact, previous reports indicated a dose-dependent 
neurotoxicity of vinorelbine treatment with predominantly distal peripheral sensory 
polyneuropathy 11,13,30. The most common symptoms were hypoesthesia, hyporeflexia, 
paresthesia and pain, but also motoric or autonomic axons were involved, which is similar to 
the neurotoxic profile of bortezomib 11,12,21,27,30,31. 
Vinorelbine toxicity typically occurs in the setting of cumulative administrations 
13,30. The dose of vinorelbine in our study was 35 mg/m2 administered once compared 
with 25 to 30 mg/m2 administered weekly when used in other cancer treatment regimens 
11,12. Repetitive administration of vinorelbine was reported to induce symptoms of mild to 
moderate neuropathy in 30 to 85% of patients after three to four weeks. After prolonged 
administration, almost all patients ultimately develop neurotoxic side effects, but neurotoxicity 
grade III/IV is usually observed in less than 5% of the patients 13,26,27,32. Both single and 
cumulative dose turned out to be significant risk factors for the development of vinorelbine 
mediated neurotoxicity 13.   
Rapid aggravation of pre-existing peripheral neurotoxicity – such as diabetic, 
alcoholic or inherited neuropathy - and rapid induction of novel CIPN have been reported 
following vinorelbine treatment in patients with prior or concomitant exposure to other 
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neurotoxic agents, mainly taxanes, anthracyclins, cisplatin or ifosfamide 11,13-16,33-37. In 
particular, vinorelbine-paclitaxel combinations were found to enhance pre-existing 
polyneuropathy, with an increased risk for further neurotoxicity even in moderate doses of 
vinorelbine and even after a one-year interval until next vinorelbine administration 14-
16,34,38. These findings underline the vulnerability for further aggravation of neurotoxicity 
following vinorelbine treatment when used after other neurotoxic compounds such as 
bortezomib, though the underlying mechanisms may not yet be fully understood 34.   
Recently, the late onset of previously not overt bortezomib induced polyneuropathy 
was reported, emerging mainly during or shortly after peripheral blood stem cell (PBSC) 
collection. A coasting phenomenon of bortezomib was suggested rather than an effect of 
compounds used between bortezomib-based induction treatment and PBSC collection 39. 
However, our data suggest that vinorelbine can independently add to bortezomib-caused 
CIPN 20,21,41. 
We observed a slow recovery rate from bortezomib-vinorelbine triggered 
polyneuropathy. In fact, half of all affected patients continued to suffer from symptoms of 
disabling CIPN after completion of HDCT treatment. Previous reports suggested that 
bortezomib- or vinorelbine-induced neuropathy were predominantly reversible after drug 
discontinuation within two to four months 17,18,21,30,42,43. In contrast, improvement of 
CIPN in our cohort remained incomplete in a significant proportion of patients. In the absence 
of effective treatment modalities for CIPN, prevention of severe CIPN remains a major goal 
of induction treatment in myeloma patients 44. 
This study was not powered to evaluate the effect of the development of CIPN on 
response and survival rates. In fact, we observed no significant differences in response and 
survival rates between myeloma patients with and without CIPN. However, developing CIPN 
can affect dosing, duration and the chemotherapy composition of myeloma treatment thereby 
affecting response to treatment 45. Consequently, longer follow-up of a larger cohort may 
be required to ultimately provide answers to these issues.  
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5. CONCLUSIONS: 
 
Our data suggest that a single administration of vinorelbine mobilization chemotherapy can 
induce relevant novel CIPN or increase pre-existing CIPN in myeloma patients after 
bortezomib-based induction chemotherapy. The majority (63%) of affected myeloma patients 
considered the burden of CIPN as “high” or “very high”, and the majority failed to completely 
recover from CIPN, with 31% reporting unchanged persisting CIPN after completion of HDCT 
treatment. Whereas the advantages of non-myelosuppressive mobilization chemotherapy - 
as opposed to high-dose cyclophosphamide – still remain significant, these observations 
indicate that vinorelbine mobilization chemotherapy is associated with significant additional 
neurotoxicity in bortezomib pretreated myeloma patients and that alternative non-neurotoxic 
chemotherapeutic agents need to be evaluated for stem cell mobilization. In our view, 
gemcitabine represents a promising candidate which has been mainly studied so far for 
mobilization in Hodgkin lymphoma patients 46-48. Consequently, we initiated a randomized 
prospective trial comparing vinorelbine and gemcitabine mobilization chemotherapy in 
myeloma patients and this trial may ultimately identify a novel role for gemcitabine as a non-
neurotoxic and effective stem cell mobilization regimen in myeloma patients.  
One might argue that mobilization chemotherapy can be omitted at all in patients with 
significant neuropathy. In fact, bortezomib based combinations as induction in young patients 
do not compromise peripheral blood stem cell collection, and most patients collect CD34+ 
cells enough for one or two transplants using G-CSF alone. However, the combination of 
chemotherapy and G-CSF allows more potent mobilization of peripheral autologous stem 
cells resulting in shorter apheresis procedures and lower costs. This is highlighted by the fact 
that 87% of all stem cell collections after vinorelbine/G-CSF stimulation in our cohort could 
be finished in a single day apheresis procedure, whereas this rate is usually decisively lower 
using G-CSF alone mobilization strategies. Thus, a strong rationale is persisting for a 
combined chemotherapy/G-CSF mobilization strategy which should acknowledge preexisting 
polyneuropathy. 
Page 17 of 27
Ac
ce
pte
d M
an
us
cri
pt
16 
 
Keller et al                                                                           Vinorelbine mobilization induces peripheral neuropathy. 
6. REFERENCES 
1 Ludwig H, Beksac M, Bladé J, Boccadoro M, Cavenagh J, Cavo M et al. Current Multiple 
Myeloma Treatment Strategies with Novel Agents: A European Perspective. The Oncologist 
2010;15:6-25. 
2 Rajkumar SV. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and 
management. American J Hematol 2011;87:79-88. 
3 Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M et al. High-dose 
therapy and autologous blood stem-cell transplantation compared with conventional 
treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized 
control trial from the Group Myeloma Autogreffe. J Clin Oncol 2005;23:9227–33. 
4 Blade J, Rosinol L, Sureda A, Ribera JM, Mediavilla J, Garcia-Larana J et al. High-dose 
therapy intensification compared with continued standard chemotherapy in multiple myeloma 
patients responding to the initial chemotherapy: long-term results from a prospective 
randomized trial from the Spanish cooperative group PETHEMA. Blood 2005;106:3755-9. 
5 Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL et al. 
International myeloma working group (IMWG) consensus statement and guidelines regarding 
the current status of stem cell collection and high-dose therapy for multiple myeloma and the 
role of plerixafor (AMD 3100). Leukemia 2009;23:1904-12. 
6 Harousseau JL, Moreau P. Autologous hematopoietic stem cell transplantation for 
multiple myeloma. N Engl J Med 2009;360:2645-54. 
7 Bargetzi MJ, Passweg J, Baertschi E, Schoenenberger A, Gwerder C, Tichelli A et al 
Mobilization of peripheral blood progenitor cells with vinorelbine and granulocyte colony-
stimulating factor in multiple myeloma patients is reliable and cost effective. Bone Marrow 
Transplant 2003;31:99-103. 
8 Heizmann M, O’Meara AC, Moosmann PR, Heijnen IA, Zuberbühler M, Fernandez P et 
al. Efficient mobilization of PBSC with vinorelbine/G-CSF in patients with malignant 
lymphoma. Bone Marrow Transplant 2009;44:75-9. 
9 Samaras P, Pfrommer S, Seifert B, Petrausch U, Mischo A, Schmidt A et al. Efficacy of 
vinorelbine plus G-CSF for CD34+ hematopoietic progenitor cell mobilization in patients with 
multiple myeloma. Biol Blood Marrow Transplant 2014 Sep 29:1-6. [Epub ahead of print]. 
10 Schmid A, Friess D, Mansouri Taleghani B, Keller P, Mueller BU, Baerlocher GM et al. 
Role of plerixafor in autologous stem cell mobilization with vinorelbine chemotherapy and 
granulocyte-colony stimulating factor in patients with myeloma: a phase II study (PAV-trial). 
Leuk Lymphoma 2014 Aug 4:1-7. [Epub ahead of print]. 
11 Carlson K, Ocean AJ. Peripheral neuropathy associatd with microtubule-targeting 
agents: occurence and management approach. Clinical Breast Cancer 2011;11:73-81. 
Page 18 of 27
Ac
ce
pte
d M
an
us
cri
pt
17 
 
Keller et al                                                                           Vinorelbine mobilization induces peripheral neuropathy. 
12 Swain SM, Arezzo JC. Neuropathy associated with microtubule inhibitors: diagnosis, 
incidence, and management. Clin Adv Hematol Oncol 2008;6:455-67. 
13 Pace A, Bove L, Nistic’o C, Ranuzzi M, Innocenti P, Pietrangeli A, Terzoli E, Jandolo B. 
Vinorelbine neurotoxicity: clinical and neurophysiological findings in 23 patients. J Neurology, 
Neurosurgery & Psychiatry 1996;61:409-11. 
14 Scalone S, Sorio R, Bortolussi R, Lombardi D, La Mura N, Veronesi A. Vinorelbine-
induced Acute Reversible Peripheral Neuropathy in a Patient with Ovarian Carcinoma 
Pretreated with Carboplatin and Paclitaxel. Acta Oncologica 2004;43:209-11. 
15 Parimodo D, Jeffers S, Muggia FM. Severe Neurotoxicity From Vinorelbine-Paclitaxel 
Combinations. J Natl Cancer Inst 1996;88:1079-80. 
16 Budman DR, Weiselberg L, O’Mara V. Severe Neurotoxicity in Vinorelbine-Paclitaxel 
Combinations. J Natl Cancer Inst 1997;89:87-8. 
17 Mohty B, El-Cheikh J, Yakoub-Agha I, Moreau P, Harousseau JL, Mohy M. Peripheral 
neuropathy and new treatments for multiple myeloma: background and practical 
recommendations. Haematologica 2010;95:311-9. 
18 Delforge M, Bladé J, Dimopoulos MA, Facon T, Kropff M, Ludwig H et al. Treatment-
related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol 
2010;11:1086-95. 
19 Koeppen S. Treatment of Multiple Myeloma: Thalidomide-, bortezomib-, and 
lenalidomide-induced peripheral neuropathy. Oncol Res Treat 2014;37:506-13. 
20 Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J et al. 
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of 
advanced multiple myeloma with bortezomib. J Clin Oncol 2006;24:3113-20. 
21 Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in 
multiple myeloma: a comprehensive review of the literature. Blood 2008;112:1-11. 
22 Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG et al. A phase 2 
study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 
2004;127:165-72. 
23 Richardson PG, Barlogie B, Berenson J, Singhai S, Jagannath S, Irwin D et al. A phase 
2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17. 
24 Lobert S, Vulevic B, Correia JJ. Interaction of vinca alkaloids with tubulin: a comparison 
of vinblastin, vincristine, and vinorelbine. Biochemistry 1996;31:5374-80. 
25 Aapro MS, Harper P, Johnson SA, Vermorken JB. Development in cytotoxic 
chemotherapy: advances in treatment utilising vinorelbine. Critical Reviews in 
Oncology/Hematology 2001;40:251-63. 
26 Galano G, Caputo M, Tecce MF, Capasso A. Efficacy and Tolerability of Vinorelbine in 
the Cancer Therapy. Current Drug Safety 2011;6:185-93. 
Page 19 of 27
Ac
ce
pte
d M
an
us
cri
pt
18 
 
Keller et al                                                                           Vinorelbine mobilization induces peripheral neuropathy. 
27 Gregory RK, Smith IE. Vinorelbine – a clinical review. Brit J Cancer 2000;82:1907-13. 
28 Capasso A. Vinorelbine in cancer therapy. Current Drug Targets 2012;13:1065-71. 
29 Binet S, Chaineau E, Fellous A, Lataste H, Krikorian A, Couzinier JP et al. 
Immunofluorescence study of the action of Navelbine; Vincristine and Vinblastine on mitotic 
and axonal microtubules. Int J Cancer 1990;46:262-6. 
30 Swain SM, Arezzo JC: Neuropathy associated with microtubule inhibitors: diagnosis, 
incidence, and management. Clin Adv Hematol Oncol 2008;6:455-67. 
31 Lonardi F. Neurotoxicity after chemotherapy with vinorelbine. Eur J Cancer 
1993;90:1794. 
32 Domenech GH, Vogel CL. A review of vinorelbine in the treatment of breast cancer. 
Clinical Breast Cancer 2001;2:113-26. 
33 Scalone S, Sorio R, Bortolussi R, Lombardi D, La Mura N, Veronesi A. Vinorelbine-
induced acute reversible peripheral neuropathy in a patient with ovarian carcinoma 
pretreated with carboplatin and paclitaxel. Acta Oncologica 2004;43:209-11. 
34 Fazeny B, Zifko U, Meryn S, Huber H, Grisold W, Dittrich C. Vinorelbine-induced 
neurotoxicity in patiens with advanced breast cancer pretreated with paclitaxel – a phase II 
study. Cancer Chemother Pharmacol 1996;39:150-6. 
35 Zelek L, Barthier S, Riofrio M. Weekly vinorelbine is an effective palliative regimen after 
failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer 
2001;92:2267-72. 
36 Leone BA, Vallejo CT, Romero AO, Perez JE, Cuevas MA, Lacava JA et al. Ifosfamide 
and vinorelbine as first-line chemotherapy for metastatic breast cancer. J Clin Oncol 
1996;14:2993-9. 
37 Dittrich C, Zufko U, Fazeny B, Fiegl M, Grisold W, Huber H. Vinorelbine after paclitaxel 
in breast cancer: cross resistance and cumulative neurotoxicity? Ann Oncol 1994;5:473-4. 
38 Ji-Youn H, Byung Gil GC, Dae Heon S, Jae Geun A, Jeong-Seob Y, Kyung Shik L. 
Vinorelbine-associated myelopathy in a patient who previously received paclitaxel. Med 
Oncol 2001;18:95-7. 
39 Tacchetti P, Terragna C, Galli M, Zamagni E, Petrucci MT, Pezzi A et al. Bortezomib- 
and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular 
analyses of a phase 3 study. American Journal of Hematology; Accepted Article, 
doi:10.1002/ajh.23835. 
40 Windebank AJ, Grisold W. Chemotherapy-induced neuropahty. J Peripher Nerv Syst 
2008;13:27-46. 
41 Badros A, Goloubeva O, Dalai JS, Can I, Thompson J, Rapoport AP et al. Neurotoxicity 
of bortezomib therapy in multiple myeloma: A single-center experience and review of the 
literature. Cancer 2007;110:1042-9. 
Page 20 of 27
Ac
ce
pte
d M
an
us
cri
pt
19 
 
Keller et al                                                                           Vinorelbine mobilization induces peripheral neuropathy. 
42 Stubblefield MD, Burstein HJ, Burton AW, Custodio CM, Deng GE, Ho M et al. NCCN 
Task force report: management of neuropathy in cancr. J Natl Compr Canc Netw 2009;7:1-
26. 
43 Cavaletti G, Jakubowiak AJ. Peripheral neuropathy during bortezomib treatment of 
multiple myeloma: a review of recent studies. Leuk Lymphoma 2010;51:1178-87. 
44 Fromme EK, Eilers KM, Mori M, Hsieh YC, Beer TM. How accurate is clinician reporting 
of chemotherapy adverse effects? A comparison with patient-reported symptoms form the 
Quality-of-Life Questionnaire C30. J Clin Oncol 2004; 22: 3485-3490. 
45 Mantyh PW. Cancer pain and its impact on diagnosis, survival and quality of life. Nature 
Rev Neuroscience 2006; 7: 797–809. 
46 Suyani E, Sucak GT, Aki SZ, Yegin ZA, Özkurt ZN, Yagci M. Gemcitabine and 
vinorelbine combination is effective in both as a salvage and mobilization regimen in 
relapsed or refractory Hodgkin lymphoma prior to ASCT. Ann Hematol 2011; 90: 658–691. 
47 Toschi L, Finocchiaro G, Bartolini S, Gioia V, Cappuzzo F. Role of gemcitabine in 
cancer therapy. Future Oncol 2005; 1: 7–17. 
48 Nabhan C, Krett N, Gandhi V, Rosen S. Gemcitabine in hematologic malignancies. Curr 
Opin Oncol 2001; 13: 514–521. 
 
Page 21 of 27
Ac
ce
pte
d M
an
us
cri
pt
8.  Figure 1 
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9.  FIGURE LEGEND 
 
Figure 1:  
A) Kaplan-Meier curves are depicted for progression free survival (PFS) and B) overall 
survival (OS) comparing myeloma patients with chemotherapy induced polyneuropathy 
(CIPN) versus patients without CIPN during first-line treatment including bortezomib-based 
induction chemotherapy, vinorelbine mobilization treatment and high-dose chemotherapy 
with melphalan supported by autologous stem cell transplantation. 
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10.1  Table 1: Patient characteristics and therapy regimens. 
 
n = 106 
Age, years, median (range) 58 (39 – 69) 
Sex, male / female, n 67 / 39 
Paraprotein IgG, n (%)  72 (68) 
                    IgA, n (%) 18 (17) 
                    IgM, n (%) 2 (2) 
                    light-chain only, n (%) 14 (13) 
Light chain kappa involved, n (%) 62 (58) 
                  lambda involved, n (%) 44 (42) 
Durie & Salmon stage I, n (%)   35 (33) 
                                   II, n (%) 27 (25) 
                                  III, n (%) 44 (42) 
                                   A, n (%) 81 (76) 
                                   B, n (%) 25 (24) 
ISS stage I, n (%) 43 (41) 
                II, n (%) 30 (28) 
               III, n (%) 33 (31) 
Cytogenetic/FISH analysis available, n (%) 55 (52) 
    no abnormalities, n (%) 3 (3) 
    standard risk, n (%) 16 (15) 
    high risk, n (%) a) 36 (34) 
Induction regimens, n (%) c)  
bortezomib, dexamethasone (VD) 62 (59) 
bortezomib, cyclophosphamide, dexamethasone  (VCD) 27 (25) 
bortezomib, doxorubicin, dexamethasone (PAD) 12 (11) 
bortezomib, thalidomide, dexamethasone (VTD) 2 (2) 
bortezomib, lenalidomide, dexamethasone  (VRD) 3 (3) 
Induction regimen, cycles, median, n (range) 4 (1 – 10) 
Maintenance therapy, n (%) 45 (42) 
lenalidomide 42 (94) 
thalidomide 2 (4) 
rituximab b) 1 (2) 
 
a)
 High-risk cytogenetics comprised hypodiploidy, deletion of chromosome 13 or 17p, presence of t(4;14) or 
t(14;16), or amplification of chromosome 1. All other abnormalities were considered standard risk; FISH: 
fluorescence in situ hybridization; ISS: international staging system. 
b) 
Given in one patient with CD20 positive 
myeloma who did not tolerate lenalidomide.
 c) 101 of 106 patients had 3 or 4 cycles of bortezomib-based 
induction treatment. 
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10.2  Table 2: Mobilization, apheresis and autologous stem cell transplantation. 
 
 n = 106 
 
Mobilization regimen:  
 vinorelbine, G-CSF a) (VG), n (%) 75 (71) 
 vinorelbine, plerixafor (VP), n (%) 21 (20) 
 vinorelbine, G-CSF, plerixafor (VGP), n (%) 10 (9) 
 
Apheresis days: 
   only 1, n (%) 
 
 
92 (87) 
    ≥1 needed, n (%) 14 (13) 
   Days until apheresis, median (range) 8 (7 – 16) 
   Duration of apheresis per day, minutes, median (range) 228 (70 – 453) 
   Peripheral WBC b) count, x 109/l, median (range) 24.60 (2.50 – 54.34) 
   Peripheral CD34+ cells, x 106/l, median, (range) 104.35 (5.00 – 378.00) 
   Peripheral CD34+ cells at apheresis, median, % (range) 0.43 (0.02 – 2.82) 
   Final CD34+ apheresis yield x 106/kg, median, (range) 13.55 (3.09 – 37.33) 
    ≥   2 x 106 / kg 2 (2) 
    ≥   5 x 106 / kg  24 (23) 
    ≥ 10 x 106 / kg  80 (75) 
 
Transplantation: 
   Transplanted CD34+ cells x 106/kg, median, (range) 
 
 
4.34 (2.04 – 8.45) 
   Days until neutrophil recovery >0.5x109/l, median, n (range) 12 (10 – 15) 
   Days until platelet recovery >20x109/l, median, n (range) 13 (8 – 23) 
   Days until platelet recovery >100x109/l, median, n (range) 21 (14 – 87) 
 
 
a) 
Granulocyte colony stimulating factor; 
b)
 white blood cell count. 
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10.3  Table 3: Chemotherapy induced polyneuropathy (CIPN).  
 
 n = 106 
 
Preexisting neuropathy a), n (%): 
 
5 (5) 
 
CIPN during induction therapy, n (%): 
  
no CIPN  44 (42) 
first occurrence or worsening of neuropathy 62 (58) 
  worsening of preexisting neuropathy                          2 (3) 
  first occurrence of neuropathy                      60 (97) 
CIPN first occurrence, weeks since start treatment, median (range) 7 (1 – 21) 
 
CIPN following mobilization therapy, n (%): 
  
no CIPN  37 (35) 
preexisting CIPN unchanged or improved 45 (42) 
first occurrence or worsening of neuropathy 24 (23) 
worsening of preexisting neuropathy 17 (71) 
first occurrence of neuropathy 7 (29) 
 
CIPN following HDCT, n (%): 
  
no CIPN  34 (32) 
preexisting CIPN unchanged or improved 67 (63) 
first occurrence or worsening of neuropathy 5 (5) 
worsening of preexisting neuropathy 2 (40) 
first occurrence of neuropathy 3 (60) 
 
CIPN during maintenance therapy, n (%): 
 
n = 45 (100) 
no CIPN  16 (36) 
preexisting CIPN unchanged or improved 23 (51) 
first occurrence or worsening or reoccurrence of neuropathy 6 (13) 
worsening or reoccurrence of preexisting neuropathy 5 (83) 
first occurrence of neuropathy 1 (17) 
    maintenance, n with CIPN per n patients with this regimen, (%)  
    lenalidomide 4 / 42 (10) 
    thalidomide 2 / 2 (100) 
    rituximab 0 / 1 (0) 
 
a) 
due to: diabetes mellitus (n=2), myeloma associated (n=2), or unknown (n=1).  
Table 3
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10.4  Table 4. Characteristics of first occurrence or aggravated chemotherapy induced 
polyneuropathy (CIPN). 
 
First occurrence of CIPN or worsening of CIPN 
during 
  
 induction therapy 
            n=62 
 
mobilization  
n=24 
   
 
Quality and severity, n (% of patients with CIPN) a) 
  
  peripheral sensory neuropathy  b) 59 (95) 23 (96) 
  I / II 46 (78) 14 (61) 
  III / IV 13 (22) 9 (39) 
  neuropathic pain 15 (24) 8 (33) 
  I / II 8 (53) 2 (25) 
  III / IV 7 (47) 6 (75) 
  peripheral motoric neuropathy c) 6 (10) 0 (0) 
  I / II 5 (83) 0 (0) 
  III / IV 1 (17) 0 (0) 
  spasms, tremor or fasciculations 6 (10) 3 (13) 
  I / II 4 (67) 2 (67) 
  III  2 (33) 1 (33) 
  ataxia 3 (5) 0 (0) 
  I / II 1 (33) 0 (0) 
  III 2 (67) 0 (0) 
 
Localization, n (% of patients with CIPN)  
  
lower extremity 24 (39) 10 (42) 
upper extremity 10 (16) 1 (4) 
lower and upper extremities 27 (44) 13 (54) 
other (generalized) 1 (2) 0 (0) 
 
Management, n (% of patients with CIPN) a) 
  
no pharmacologic treatment  37 (60) 12 (50) 
Pharmacologic treatment a) 13 (30) 12 (50) 
 NSAID 1 (8) 2 (17) 
 paracetamol, metamizol 2 (15) 3 (25) 
 pregabalin, gabapentin 10 (77)  9 (75) 
 opioids 3 (23) 2 (17) 
 magnesium 0 (0) 1 (8) 
 tricyclic antidepressants 1 (8) 2 (17) 
  Dose reduction / temporary interruption of therapy           12 (19)             ---- 
  Discontinuation of therapy 8 (13) ---- 
   
 
a)
 Percentages may sum to more than 100% since some issues may apply more than once in some 
patients. 
b)
 Peripheral sensory neuropathy included paresthesia, dysesthesia, hypesthesia, 
hyperesthesia, hyporeflexia, hypalgesia, and decreased temperature sensation. 
c) 
Predominantly 
included muscle weakness. 
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